Related Experiment Video
Updated: May 31, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
[Antipsychotics and diabetes: pathophysiology and current recommendations].
Myriam Déban Kuflom1, Marc Rajakoski1, Vasiliki Galani2
1Service d'endocrinologie, diabétologie et métabolisme, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue Medicale Suisse
|May 29, 2026
Summary
Antipsychotic medications for psychotic disorders raise diabetes and metabolic syndrome risks, increasing cardiovascular issues. Clozapine and olanzapine pose the highest risks, necessitating improved monitoring and early intervention.
Area of Science:
- Pharmacology
- Endocrinology
- Cardiology
Background:
- Antipsychotic drugs are crucial for treating psychotic disorders.
- These medications are associated with increased risks of diabetes and metabolic syndrome.
- This elevates cardiovascular morbidity and mortality rates.
Purpose of the Study:
- To review the risks of metabolic complications associated with antipsychotic drug use.
- To discuss the mechanisms underlying these metabolic effects.
- To emphasize the need for improved monitoring and management strategies.
Main Methods:
- Literature review of studies on antipsychotic drugs and metabolic side effects.
- Analysis of mechanisms involving central and peripheral pathways.
- Evaluation of current guidelines and implementation challenges.
Main Results:
- Risk of diabetes and metabolic syndrome varies among antipsychotic agents.
- Clozapine and olanzapine exhibit the highest liability for metabolic complications.
- Mechanisms include hypothalamic and peripheral actions, leading to insulin resistance and hormonal dysregulation, sometimes independent of weight gain.
Conclusions:
- Metabolic monitoring for patients on antipsychotics is inadequately implemented.
- Systematic screening and early preventive strategies are vital.
- Reducing metabolic complications is essential to lower cardiovascular risks in this population.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...